The Phase II THULITE trial will analyze the safety and efficacy of BI 1815368, an investigational oral therapy designed to ...

Biljana Naumovic, US President, oncology, solid tumor, Johnson & Johnson Innovative Medicine, shares how the company is ...

Results from the Phase III ZENITH trial show that patients treated with Winrevair (sotatercept-csrk) for pulmonary arterial ...

Accelerated approval was based on results from the Phase I/II LINKER-MM1 trial, which showed a 70% objective response rate in ...

Expert panelists emphasize the importance of trusted data sources, strong payer partnerships, economic incentives, and ...

Due to popularity of the medications, GLP-1s were in short supply up until recently. Obesity is a common issue among ...

Former Philadelphia Eagles quarterback Rodney Peete joined Sumitomo Pharma America’s Time to Go campaign. 1 The promotional ...

Pharmaceutical Executive: How is federal policy reshaping life sciences investments? John Stanford: Federal policy is ...

Updated label allows Neuraceq to be used in selecting patients for amyloid-targeting therapies and includes the use of ...

The supplemental premarket approval application is supported by Phase III data, which showed significant improvements in neck ...

Biljana Naumovic, US President, oncology, solid tumor, Johnson & Johnson Innovative Medicine, discusses the importance of ...

Results from the Phase III SUNMO trial show that the Lunsumio and Polivy combination achieved statistically significant ...